Zimmer Biomet Company Top Insiders
ZBH Stock | USD 96.88 0.36 0.37% |
Under 64% of Zimmer Biomet's corporate insiders are selling. The analysis of insiders' sentiment of trading Zimmer Biomet Holdings stock suggests that many insiders are alarmed at this time. Zimmer Biomet employs about 17 K people. The company is managed by 38 executives with a total tenure of roughly 203 years, averaging almost 5.0 years of service per executive, having 447.37 employees per reported executive.
Larry Glasscock Chairman Independent Non-Executive Chairman of the Board |
Bryan Hanson Chairman Chairman of the Board, President, Chief Executive Officer |
Insider Sentiment 36
Mostly Selling
Selling | Buying |
Latest Trades
2025-06-26 | Ro Khanna | Disposed @ 91.93 | |||
2025-06-16 | Ro Khanna | Acquired @ 92.15 | |||
2025-06-11 | Sang Yi | Disposed 1000 @ 95 | View | ||
2025-06-10 | Ro Khanna | Acquired @ 94.85 | |||
2025-05-28 | Ro Khanna | Disposed @ 92.14 | |||
2025-05-19 | Ro Khanna | Disposed @ 95.8 | |||
2025-05-15 | Robert Bresnahan, Jr. | Disposed @ 96.68 | |||
2025-05-02 | Ro Khanna | Disposed @ 102.08 | |||
2025-04-23 | Ro Khanna | Acquired @ 99.54 | |||
2025-04-08 | Robert Bresnahan, Jr. | Acquired @ 102.73 | |||
2025-03-05 | Lori Winkler | Disposed 1443 @ 104.4 | View |
Monitoring Zimmer Biomet's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Zimmer Biomet's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Zimmer Biomet Holdings. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Zimmer Biomet's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. Zimmer Biomet's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Zimmer Biomet's future performance. Based on our forecasts, it is anticipated that Zimmer will maintain a workforce of under 17000 employees by August 2025.Zimmer Biomet's latest congressional trading
Congressional trading in companies like Zimmer Biomet Holdings, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Zimmer Biomet by those in governmental positions are based on the same information available to the general public.
2025-07-10 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
2025-05-08 | Representative Rob Bresnahan | Acquired Under $15K | Verify | ||
2025-03-13 | Representative Julie Johnson | Acquired Under $15K | Verify | ||
2022-08-13 | Representative Susie Lee | Acquired $15K to $50K | Verify | ||
2017-01-04 | Senator John Reed | Acquired Under $15K | Verify |
Zimmer Biomet Management Team Effectiveness
The company has Return on Asset of 0.0442 % which means that on every $100 spent on assets, it made $0.0442 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0732 %, implying that it generated $0.0732 on every 100 dollars invested. Zimmer Biomet's management efficiency ratios could be used to measure how well Zimmer Biomet manages its routine affairs as well as how well it operates its assets and liabilities. The Zimmer Biomet's current Return On Tangible Assets is estimated to increase to 0.17, while Return On Capital Employed is projected to decrease to 0.06. As of now, Zimmer Biomet's Asset Turnover is decreasing as compared to previous years.The current Common Stock Shares Outstanding is estimated to decrease to about 164.9 M. The current Net Income Applicable To Common Shares is estimated to decrease to about 631.7 M
Zimmer Biomet Workforce Comparison
Zimmer Biomet Holdings is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 406,293. Zimmer Biomet holds roughly 17,000 in number of employees claiming about 4% of equities under Health Care industry.
Zimmer Biomet Profit Margins
The company has Net Profit Margin of 0.12 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.18 %, which entails that for every 100 dollars of revenue, it generated $0.18 of operating income.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.8 | 0.7146 |
|
| |||||
Operating Profit Margin | 0.22 | 0.1674 |
|
|
Zimmer Biomet Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zimmer Biomet insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zimmer Biomet's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Zimmer Biomet insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-09-01 | 0.5 | 1 | 2 | 2,631 | 3,323 |
2025-06-01 | 7.0 | 28 | 4 | 42,599 | 2,623 |
2025-03-01 | 1.0208 | 49 | 48 | 380,334 | 217,534 |
2024-12-01 | 5.5 | 11 | 2 | 34,148 | 23,045 |
2024-09-01 | 5.0 | 10 | 2 | 4,843 | 3,190 |
2024-06-01 | 6.2 | 31 | 5 | 18,766 | 14,668 |
2024-03-01 | 0.975 | 39 | 40 | 194,901 | 134,290 |
2023-12-01 | 1.0 | 10 | 10 | 4,346 | 54,956 |
2023-09-01 | 6.6667 | 20 | 3 | 31,806 | 8,078 |
2023-06-01 | 15.0 | 30 | 2 | 15,737 | 825.00 |
2023-03-01 | 1.625 | 26 | 16 | 162,668 | 83,458 |
2022-12-01 | 1.8571 | 13 | 7 | 17,129 | 26,399 |
2022-09-01 | 2.5 | 10 | 4 | 6,105 | 8,181 |
2022-06-01 | 15.5 | 31 | 2 | 22,869 | 698.00 |
2022-03-01 | 9.75 | 39 | 4 | 467,147 | 64,913 |
2021-12-01 | 0.4839 | 15 | 31 | 64,115 | 200,119 |
2021-09-01 | 6.0 | 12 | 2 | 55,755 | 4,767 |
2021-06-01 | 10.0 | 30 | 3 | 18,583 | 1,677 |
2021-03-01 | 1.5789 | 30 | 19 | 288,100 | 46,869 |
2020-12-01 | 1.1538 | 15 | 13 | 44,019 | 79,541 |
2020-09-01 | 3.6667 | 11 | 3 | 7,069 | 6,288 |
2020-06-01 | 15.5 | 31 | 2 | 25,622 | 9,717 |
2020-03-01 | 2.3571 | 33 | 14 | 391,443 | 47,148 |
2019-12-01 | 1.1111 | 20 | 18 | 32,522 | 48,096 |
2019-09-01 | 1.8571 | 13 | 7 | 114,086 | 74,745 |
2019-06-01 | 7.5 | 30 | 4 | 25,796 | 11,639 |
2019-03-01 | 3.5385 | 46 | 13 | 365,528 | 22,627 |
2018-12-01 | 8.0 | 16 | 2 | 65,078 | 12,622 |
2018-09-01 | 2.1429 | 15 | 7 | 61,162 | 71,701 |
2018-06-01 | 3.7143 | 26 | 7 | 31,431 | 20,582 |
2018-03-01 | 5.8333 | 35 | 6 | 588,586 | 48,557 |
2017-12-01 | 1.8571 | 13 | 7 | 339,212 | 25,762 |
2017-09-01 | 1.5556 | 14 | 9 | 26,361 | 33,282 |
2017-06-01 | 1.7619 | 37 | 21 | 174,048 | 283,208 |
2017-03-01 | 1.6818 | 37 | 22 | 523,484 | 270,163 |
2016-12-01 | 5.0 | 10 | 2 | 6,975 | 10,100 |
2016-09-01 | 0.9167 | 11 | 12 | 19,968 | 66,618 |
2016-06-01 | 3.0909 | 34 | 11 | 23,585 | 50,622 |
2016-03-01 | 1.5714 | 33 | 21 | 574,565 | 40,720,036 |
2015-12-01 | 2.25 | 9 | 4 | 6,733 | 10,844 |
2015-06-01 | 1.0385 | 54 | 52 | 798,845 | 209,284 |
2015-03-01 | 1.1429 | 24 | 21 | 170,302 | 139,375 |
2014-12-01 | 0.875 | 14 | 16 | 91,430 | 138,016 |
2014-09-01 | 1.6667 | 10 | 6 | 82,642 | 92,473 |
Zimmer Biomet Notable Stakeholders
A Zimmer Biomet stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Zimmer Biomet often face trade-offs trying to please all of them. Zimmer Biomet's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Zimmer Biomet's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Larry Glasscock | Independent Non-Executive Chairman of the Board | Profile | |
Bryan Hanson | Chairman of the Board, President, Chief Executive Officer | Profile | |
Ellison Humphrey | Senior Vice President, Chief Transformation Officer | Profile | |
Derek Davis | Chief Accounting Officer, Vice President, Controller | Profile | |
Ivan Tornos | Group President - Global Businesses and Americas | Profile | |
Suketu Upadhyay | Chief Financial Officer, Executive Vice President | Profile | |
Sang Yi | President Asia Pacific | Profile | |
Chad Phipps | Senior Vice President, General Counsel, Secretary | Profile | |
Mark Bezjak | President Americas | Profile | |
Brian Hatcher | SET President | Profile | |
Arthur Higgins | Independent Director | Profile | |
Michael Michelson | Independent Director | Profile | |
Christopher Begley | Lead Independent Director | Profile | |
Betsy Bernard | Independent Director | Profile | |
Maria Hilado | Independent Director | Profile | |
Syed Jafry | Independent Director | Profile | |
Michael Farrell | Independent Director | Profile | |
Zachary CPA | Director Relations | Profile | |
Gail Boudreaux | Independent Director | Profile | |
Robert Hagemann | Independent Director | Profile | |
Chad JD | General VP | Profile | |
Angela Main | Global VP | Profile | |
Sreelakshmi Kolli | Independent Director | Profile | |
Didier Deltort | President - Europe, Middle East and Africa | Profile | |
Carrie Nichol | Chief Accounting Officer, Vice President Controller | Profile | |
Kenneth Tripp | Senior Logistics | Profile | |
Nitin Goyal | Chief Science, Technology and Innovation Officer | Profile | |
Wilfred Zuilen | President - Europe, Middle East and Africa | Profile | |
JehanZeb Noor | Chief Staff | Profile | |
Zeeshan Tariq | Senior Officer | Profile | |
Keri Mattox | Senior Vice President - Investor Relations, Chief Communications Officer | Profile | |
Rachel Ellingson | Senior Vice President Chief Strategy Officer, Executive Officer | Profile | |
Kristen Cardillo | Senior Officer | Profile | |
Nitin MD | Technology Science | Profile | |
Paul Stellato | Controller VP | Profile | |
Lori Winkler | Chief Human Resource Officer, Senior Vice President | Profile | |
David DeMartino | Senior Relations | Profile | |
Shaun Braun | Senior Officer | Profile |
About Zimmer Biomet Management Performance
The success or failure of an entity such as Zimmer Biomet Holdings often depends on how effective the management is. Zimmer Biomet management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Zimmer management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Zimmer management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.12 | 0.17 | |
Return On Capital Employed | 0.07 | 0.06 | |
Return On Assets | 0.04 | 0.04 | |
Return On Equity | 0.07 | 0.07 |
Zimmer Biomet Workforce Analysis
Traditionally, organizations such as Zimmer Biomet use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Zimmer Biomet within its industry.Zimmer Biomet Manpower Efficiency
Return on Zimmer Biomet Manpower
Revenue Per Employee | 451.7K | |
Revenue Per Executive | 202.1M | |
Net Income Per Employee | 53.2K | |
Net Income Per Executive | 23.8M | |
Working Capital Per Employee | 130.6K | |
Working Capital Per Executive | 58.4M |
Complementary Tools for Zimmer Stock analysis
When running Zimmer Biomet's price analysis, check to measure Zimmer Biomet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zimmer Biomet is operating at the current time. Most of Zimmer Biomet's value examination focuses on studying past and present price action to predict the probability of Zimmer Biomet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zimmer Biomet's price. Additionally, you may evaluate how the addition of Zimmer Biomet to your portfolios can decrease your overall portfolio volatility.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |